Monalisa Mild — Hy-BRID HA Filler for Perioral Lines & Crow’s Feet (400µm)

Monalisa Mild is GENOSS’s medium-particle variant — 24 mg/mL cross-linked HA + 0.3% lidocaine with 400µm particle size via Hy-BRID technology. Engineered for superficial-to-mid dermal placement targeting perioral lines, crow’s feet, and lip contour refinement. BDDE residue undetectable; endotoxin below international safety thresholds.

Monalisa Mild with Lidocaine is manufactured by GENOSS Co. Ltd., a South Korea-based medical device and pharmaceutical company established in 2007. The product is part of the Monalisa dermal filler range, which is distributed across multiple international markets. Regulatory status: KFDA registered · CE 2195 · KGMP · ISO 13485 · ISO 9001.

Monalisa Mild with Lidocaine contains 24 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using GENOSS Co. Ltd.’s Hy-BRID Cross-Linking Technology (400µm particles) technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per GENOSS Co. Ltd.’s clinical data, Monalisa Mild with Lidocaine delivers Up to 6 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Superficial-to-mid dermis placement typically delivers the longer end of the duration range.

Monalisa Mild with Lidocaine is engineered for superficial-to-mid dermis placement. The standard recommended needle is 27G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Monalisa Mild with Lidocaine regulatory status: KFDA registered · CE 2195 · KGMP · ISO 13485 · ISO 9001. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Monalisa Mild with Lidocaine between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Monalisa Mild with Lidocaine uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Monalisa Mild with Lidocaine can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Both use GENOSS’s Hy-BRID cross-linking with 24 mg/mL HA + 0.3% lidocaine but differ in particle size and intended depth. Monalisa Soft (200µm) is for superficial dermal placement — tear trough, very fine periorbital lines, thin-skinned zones. Monalisa Mild (400µm) is for superficial-to-mid dermal placement — perioral lines, crow’s feet, lip contour. Mild’s larger particles provide slightly more structure for moderate wrinkles while remaining soft enough for refined work.